Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) traded down 0.4% during mid-day trading on Friday . The company traded as low as $0.7655 and last traded at $0.79. 19,355 shares changed hands during mid-day trading, a decline of 37% from the average session volume of 30,777 shares. The stock had previously closed at $0.7929.
Matinas Biopharma Stock Performance
The business’s fifty day moving average is $1.24 and its 200-day moving average is $1.28. The firm has a market cap of $5.06 million, a P/E ratio of -0.23 and a beta of 1.32.
Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter.
About Matinas Biopharma
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.
Read More
- Five stocks we like better than Matinas Biopharma
- What Are Earnings Reports?
- Synopsys Sees Bullish Shift as Ansys Integration Drives Growth
- Should You Invest in Penny Stocks?
- The Best Holiday Present You Can Give Yourself? Costco Stock
- Why Are Stock Sectors Important to Successful Investing?
- Why Zscaler Stock Could Be Ready to Bounce After a 30% Selloff
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
